Rothschild Investment LLC’s Akero Therapeutics AKRO Stock Holding History

Rothschild Investment LLC’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-120	Closed	-$5.7K	–	3430
2025 Q3	$5.7K	Sell	120 -30	-20%	-$1.45K	﹤0.01%	1657
2025 Q2	$8K	Buy	150 +40	+36%	+$1.82K	﹤0.01%	1304
2025 Q1	$4.45K	Buy	110 +20	+22%	+$848	﹤0.01%	1495
2024 Q4	$2.5K	Buy	90 +25	+38%	+$757	﹤0.01%	1664
2024 Q3	$1.86K	Buy	65 +45	+225%	+$1.17K	﹤0.01%	1767
2024 Q2	$469	Buy	20 +15	+300%	+$321	﹤0.01%	2060
2024 Q1	$126	Buy	+5	New	+$120	﹤0.01%	2054

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rothschild Investment LLC's AKRO Position: Q4 2025 in Review

Rothschild Investment LLC sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 120 shares — an estimated $5.7K sold.

Rothschild Investment LLC first reported a position in AKRO in Q1 2024 and held it in 7 quarters. The position peaked at $8K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Rothschild Investment LLC reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Rothschild Investment LLC sold 120 Akero Therapeutics shares in Q4 2025, an estimated $5.7K.
Rothschild Investment LLC first reported a position in Akero Therapeutics in Q1 2024 and held it in 7 quarters.
Rothschild Investment LLC's Akero Therapeutics position peaked at $8K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Rothschild Investment LLC's 13F filing for Q4 2025, filed 10 Feb 2026.